Business
Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Tividenofusp alfa (DNL310; ETV:IDS) launch readiness established ahead of April 5, 2026 Prescription Drug User Fee Act (PDUFA) target action date for Hunter syndromeDNL126 (ETV:SGSH) Phase 1/2 preliminary data presented at 2026 WORLDSymposium™, supporting plans to pursue an accelerated approval path in Sanfilippo syndrome type AStart-up activities underway for DNL628 (OTV:MAPT) Phase 1b study for Alzheimer's disease and DNL952 (ETV:GAA) Phase 1 study for late-onset Pompe diseaseTransportVehicle™
About this update from Denali Therapeutics Inc.
[{"type":"image","alt":"Denali Therapeutics Inc.","displaySize":"","headline":null,"caption":"Denali Therapeutics Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":48,"url":"https://media.zenfs.com/en/globenewswire.com/649c66e2c9a2517794304178998a40c5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/HTEDoT2Wj28BopRS.0dZLg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTY3O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/649c66e2c9a2517794304178998a40c5","width":300,"height":48}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Tividenofusp alfa (DNL310; ETV:IDS) launch readiness established ahead of April 5, 2026 Prescription Drug User Fee Act (PDUFA) target action date for Hunter syndrome","length":170,"tagName":"p"}]},{"val":[{"type":"text","content":"DNL126 (ETV:SGSH) Phase 1/2 preliminary data presented at 2026 WORLDSymposium™, supporting plans to pursue an accelerated approval path in Sanfilippo syndrome type A","length":165,"tagName":"p"}]},{"val":[{"type":"text","content":"Start-up activities underway for DNL628 (OTV:MAPT) Phase 1b study for Alzheimer's disease and DNL952 (ETV:GAA) Phase 1 study for late-onset Pompe disease","length":157,"tagName":"p"}]},{"val":[{"type":"text","content":"TransportVehicle™ platform and clinical pipeline progressing across lysosomal storage disorders and neurodegenerative diseases","length":126,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":618,"olType":false},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided business highlights.","length":231,"tagName":"p"},{"type":"text","content":"“In 2025, we made meaningful progress toward delivering urgently needed treatment options for people living with neurodegenerative diseases and lysosomal storage disorders, building on the strong scientific foundation that defines Denali,” said Ryan Watts, Ph.D., Chief Executive Officer of Denali Therapeutics. “We established commercial readiness for the anticipated launch of tividenofusp alfa for individuals and families affected by Hunter syndrome and continued advancing our TransportVehicle platform across serious neurologic and systemic diseases that impact millio...